Abstract
Approximately 7% of women will have distant metastases at time of presentation with breast cancer. Routine use of bone scintigraphy is no longer recommended due to a higher false positive than true positive rate. Bone scintigraphy is used in addition to CT of the chest, abdomen and pelvis (CT-TAP) in patients with clinical stage II and III disease. The aim of this study was to evaluate the additional diagnostic yield from bone scintigraphy in patients with newly diagnosed breast cancer undergoing staging with CT-TAP.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical oncology (Royal College of Radiologists (Great Britain))
Paper Title
Journal
Date
